Marchidann, Adrian <br/><br/>
Expansion of Intravenous Tissue Plasminogen Activator Eligibility Beyond National Institute of Neurological Disorders and Stroke and European Cooperative Acute Stroke Study III Criteria.  [electronic resource] 

 -  Neurologic clinics  May 2015 
 - 381-400 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1557-9875 
<br/><br/><label>Standard No.: </label>10.1016/j.ncl.2015.01.004  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Clinical Trials as Topic<br/>Fibrinolytic Agents--therapeutic use<br/>Humans<br/>National Institute of Neurological Disorders and Stroke (U.S.)<br/>Stroke--drug therapy<br/>Tissue Plasminogen Activator--therapeutic use<br/>United States